front-line osimertinib significantly lengthens overall survival in egfr-mutation positive nsclc
Published 4 years ago • 3.4K plays • Length 5:06Download video MP4
Download video MP3
Similar videos
-
1:36
comment: front-line osimertinib significantly lengthens overall survival in egfr-mutation positi...
-
1:46
osimertinib after surgery significantly improves survival in resected egfr-mutated nsclc
-
5:26
first-line osimertinib in egfr mutant ansclc patients: progression pattern and safety in the rea...
-
2:21
osimertinib ipilimumab in egfr-mutated nsclc
-
9:49
osimertinib as frontline therapy for egfr-positive nsclc
-
6:43
sequential afatinib and osimertinib in egfr mutation-positive nsclc patients: updated results
-
6:51
osimertinib as frontline therapy in egfr-positive nsclc
-
5:18
frontline therapy for egfr plus nsclc: osimertinib’s impact
-
8:44
flaura final analysis: osimertinib for first-line egfrm nsclc
-
3:31
osimertinib plus gefitinib for treatment of egfr-mutated non-small cell lung cancer
-
1:45
phase iii data support frontline osimertinib in egfr-mutant lung cancers
-
3:02
osimertinib in advanced egfr t790m-mutant nsclc
-
11:47
osimertinib as first-line treatment for egfr mutation-positive advanced nsclc? (bmic-017)
-
0:40
copy of dr. west on fda approval of frontline osimertinib in egfr nsclc
-
15:35
asco 2020: latest developments in egfr-mutated non-small cell lung cancer
-
17:55
front-line targeted therapy for advanced egfr-positive disease
-
0:48
investigating osimertinib for brain activity in egfr-mutated lung cancer
-
2:20
osimertinib in advanced non–small-cell lung cancer
-
6:30
osimertinib adjuvant therapy in patients with early stage egfr mutated nsclc after tumour resection